Skip to main content

Table 1 Patient characteristics according to miRNA-126 and MVD

From: The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort

Parameter

Number

miRNA-126

p-value

MVD

p-value

 

(n = 560) (%)

(n = 560)

 

(n = 555)

 

Median (95% CI)

 

Median (95% CI)

Sex

     

Male

241 (43)

2.49 (2.38-2.59)

0.61

10.7 (10.3-11.0)

0.17

Female

319 (57)

2.47 (2.40-2.53)

 

10.3 (10.0-10.7)

 

Age, median 74

     

≥74

280 (50)

2.49 (2.42-2.56)

0.31

10.7 (10.3-11.0)

0.11

<74

280 (50)

2.44 (2.34-2.53)

 

10.3 (10.0-10.7)

 

T category

     

T4

73 (13)

2.20 (2.03-2.42)

0.0004

10.3 (10.0-11.3)

0.59

T3

487 (87)

2.50 (2.44-2.56)

 

10.3 (10.0-10.7)

 

Malignancy grade

     

High*

107 (19)

2.33 (2.17-2.48)

0.01

10.0 (9.3-10.7)

0.03

Medium + Low

453 (81)

2.49 (2.43-2.56)

 

10.7 (10.3-10.7)

 

Localisation

     

Right

286 (51)

2.48 (2.39-2.54)

0.45

10.3 (10.0-10.7)

0.75

Left

274 (49)

2.48 (2.38-2.56)

 

10.3 (10.0-10.7)

 

Perforation

     

Yes

49 (9)

2.36 (2.05-2.42)

0.003

11.0 (10.0-12.0)

0.19

No

511 (91)

2.49 (2.43-2.56)

 

10.3 (10.0-10.7)

 

Fixation

     

Yes

100 (18)

2.36 (2.12-2.47)

0.0009

10.7 (10.3-11.3)

0.15

No

460 (82)

2.50 (2.43-2.57)

 

10.3 (10.0-10.7)

 

Lymph nodes a

     

≥12

251 (45)

2.49 (2.39-2.54)

0.96

10.7 (10.0-11.0)

0.10

<12

306 (55)

2.47 (2.39-2.56)

 

10.3 (10.0-10.7)

 

Neuronal invasion

     

Yes

47 (8)

2.38 (2.16-2.59)

0.66

10.0 (9.0-10.7)

0.29

No

513 (92)

2.48 (2.42-2.53)

 

10.3 (10.3-10.7)

 

Vascular invasion

     

Yes

67 (12)

2.48 (2.31-2.65)

0.81

10.3 (10.0-11.0)

0.98

No

493 (88)

2.48 (2.42-2.53)

 

10.3 (10.0-10.7)

 

MSI status

     

MSI

159 (28)

2.30 (2.17-2.46)

0.003

10.3 (10.0-11.0)

0.83

MSS

401 (72)

2.53 (2.46-2.59)

 

10.3 (10.0-10.7)

 
  1. CI: confidence interval; miRNA-126: microRNA-126; MSI: microsatelite instability; MSS: microsatelite stable; MVD: microvessel density.
  2. aNot assessed for all patients.
  3. *Including mucinous and sigillocellular adenocarcinomas.
  4. Significant p-values are highlighted in bold.